Business
MTA secured to assess CTOT-19 samples
MTA secured to assess CTOT-19 samples.
About this update from Verici Dx Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 3691V\n Verici Dx PLC\n 14 April 2021\n \n \n \n \n Verici Dx plc\n \n \n (\"Verici Dx\" or the \"Company\") \n \n \n \n \n \n Material Transfer Agreement secured to assess CTOT-19 samples using\n Clarava™\n and Tuteva™\n \n \n Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces it has entered into a Material Transfer Agreement (\"MTA\") with the Icahn School of Medicine at Mount Sinai and Principal Investigator Dr. Peter Heeger, to allow access to samples from the CTOT-19 (Clinical Trials in Organ Transplant1) trial in an effort to validate the performance and development of commercial tests designed to improve short and long-term graft and patient survival.\n \n The Company has secured an agreement, providing access to de-identified samples generated from participants in the CTOT-19 study, titled: \"Effects of Inhibiting at Early Inflammation in Kidney Transplant Patients.\"2 This randomised controlled trial was initiated in November 2015 with the aim to enrol 300 kidney transplant recipients at 15 transplant centres in the US and Canada, with a primary completion date expected July 2021. \n \n Access to samples from this important clinical trial, in addition to the Verici Dx clinical study already ongoing for the validation of Clarava™ and Tuteva™, provides the Company with a large and well-characterised sample group. The Company's laboratory will conduct a blinded evaluation of samples in Clarava™ and Tuteva™ and work with investigators, including Dr. Peter Heeger, to characterise results following the data lock later this year. The Company will further support this important CTOT programme by providing full transcriptomic sequencing to the investigators to augment ongoing research in mechanistic studies.\n \n \n \n \n Dr. Barbara Murphy, Chair of Science Advisory Board of Verici Dx, commented:\n \"We are extremely pleased for the opportunity this MTA represents and to collaborate with Dr. Peter Heeger and CTOT.\n We look forward to the assessment of the clinical performance validation of both Clarava and Tuteva as laboratory developed tests and to furthering research endeavours in organ transplant.\"\n \n \n \n \n \n The test described is based on technology developed by Mount Sinai fac...